BioNTech SE Stock price

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
92.97 USD +1.38% Intraday chart for BioNTech SE +3.30% -11.91%
Sales 2024 * 2.83B 3.05B Sales 2025 * 2.86B 3.08B Capitalization 20.43B 22.03B
Net income 2024 * -487M -525M Net income 2025 * -333M -359M EV / Sales 2024 * 2.3 x
Net cash position 2024 * 13.91B 15.01B Net cash position 2025 * 14.89B 16.06B EV / Sales 2025 * 1.94 x
P/E ratio 2024 *
-41.4 x
P/E ratio 2025 *
-51.4 x
Employees 6,133
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.48%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.38%
1 week+3.30%
Current month+4.51%
1 month+0.19%
3 months-13.56%
6 months-9.84%
Current year-11.91%
More quotes
1 week
90.78
Extreme 90.78
93.56
1 month
85.21
Extreme 85.2129
97.50
Current year
85.21
Extreme 85.2129
114.70
1 year
85.21
Extreme 85.2129
131.52
3 years
85.21
Extreme 85.2129
464.00
5 years
12.53
Extreme 12.525
464.00
10 years
12.53
Extreme 12.525
464.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 08-06-01
Founder 57 08-06-01
Director of Finance/CFO 60 21-06-30
Members of the board TitleAgeSince
Director/Board Member 69 21-12-31
Director/Board Member 67 08-06-01
Chairman 53 08-06-01
More insiders
Date Price Change Volume
24-03-27 92.97 +1.38% 378,283
24-03-26 91.7 -1.40% 360,719
24-03-25 93 +1.27% 489,538
24-03-22 91.83 -0.17% 558,715
24-03-21 91.99 +2.21% 1,349,461

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
85.92 EUR
Average target price
109.1 EUR
Spread / Average Target
+26.95%
Consensus
  1. Stock
  2. Equities
  3. Stock BioNTech SE - Nasdaq